Severe ototoxicity in a health care worker who received postexposure prophylaxis with stavudine, lamivudine, and nevirapine after occupational exposure to HIV [2]

Clinical Infectious Diseases

Volumn 34, Issue 3, 2002, Pages 418-419

  Rey, D ^a   L'Heritier A ^a   Lang, J M ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; CASE REPORT; DIARRHEA; FEMALE; HEARING LOSS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT PERIOD; LETTER; NAUSEA; OTOTOXICITY; PRIORITY JOURNAL; PROPHYLAXIS;

ADULT; ANTI-HIV AGENTS; CHEMOPREVENTION; FEMALE; HEALTH PERSONNEL; HEARING DISORDERS; HIV INFECTIONS; HUMANS; LAMIVUDINE; NEVIRAPINE; OCCUPATIONAL EXPOSURE; STAVUDINE;

EID: 0036467059     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/324368     Document Type: Letter

References (9)

1. Ototoxicity associated with use of nucleoside analog reverse transcriptase inhibitors: A report of 3 possible cases and review of the literature
2. Ototoxicity associated with dideoxycytidine
3. Irreversible ototoxicity associated with zalcitabine
4. Acoustic neuropathy associated with zalcitabine-induced peripheral neuropathy
5. Deafness caused by didanosine
6. Antiviral therapy in a child with pediatric human immunodeficiency virus (HIV): Case study of audiologic findings
7. Hearing loss and antiretroviral therapy in patients infected with HIV-1
8. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: A looming obstacle for long-term antiretroviral therapy?
9. Association of mitochondrial DNA deletions and cochlear pathology: A molecular biologic tool